Short-term daily teriparatide in patients with rheumatoid arthritis

References

• Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuy AE, van de Stadt RJ, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFKB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9. doi:10.1136/ard.2005.044198
   PubMed Web of Science ®Google Scholar
• Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5:65, doi:10.1007/s11926-003-0085-6
   PubMedGoogle Scholar
• Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008:CD001155. doi:10.1002/14651858.CD001155.pub2
   PubMed Web of Science ®Google Scholar
• Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008:CD004523. doi:10.1002/14651858.CD004523.pub3
   Web of Science ®Google Scholar
• den Uyl D, Bultink IE, Lems WF. Glucocorticoid-induced osteoporosis. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S93–S8.
   PubMed Web of Science ®Google Scholar
• Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, et al. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic disease: a 12-month, randomized, double-blind, placebo-controlled trial. Scand J Rheumatol. 2012;41(4):260–6. doi:10.3109/03009742.2012.664647
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Baiardi P, Abdi-Ali L, Povino MR, Dolenti S, et al. Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids. Clin Exp Rheumatol. 2009;27:567–73. doi:10.2174/1381612043383737
   PubMed Web of Science ®Google Scholar
• Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87(6):469–84. doi:10.1007/s00223-010-9420-x
   PubMed Web of Science ®Google Scholar
• Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr Pharm Des. 2004;10:2615–27. doi:10.2174/1381612043383737
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41. doi:10.1056/NEJM200105103441904
   PubMed Web of Science ®Google Scholar
• Ebina K, Hashimoto J, Shi K, Kashii M, Hirano M, Toshikawa H. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients. Osteoporos Int. 2014;25(12):2755–65. doi:10.1007/s00198-014-2819-x
   PubMed Web of Science ®Google Scholar
• Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55. doi:10.1002/art.24879
   PubMed Web of Science ®Google Scholar
• Pietrogrande L, Raimondo E. Teriparatide in the treatment of non-unions: scientific and clinical evidences. Injury. 2013;44(Suppl 1):S54–S7. doi:10.1016/S0020-1383(13)70013-5
   PubMed Web of Science ®Google Scholar
• Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14. doi:10.1359/jbmr.090731
   PubMed Web of Science ®Google Scholar
• Chiang CY, Zebaze RM, Ghasem-Zadeh A, Luliano-Burns S, Hardidge A, Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52(1):360–5. doi:10.1016/j.bone.2012.10.006
   PubMed Web of Science ®Google Scholar
• Lee YK, Ha YC, Kang BJ, Chang JS, Koo KH. Predicting need for fixation of atypical femoral fracture. J Clin Endocrinol Metab. 2013;98(7):2742–5. doi:10.1210/jc.2012-4322
   PubMed Web of Science ®Google Scholar
• Gomberg SJ, Wustrack RL, Napoli N, Amaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year histry of continuous alendronate therapy. J Clin Endocrin Metab. 2011;96(6):1627–32. doi:10.1210/jc.2010-2520
   PubMed Web of Science ®Google Scholar
• Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH, et al. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause. 2012;19(12):1360–3. doi:10.1097/gme.0b013e318260143d
   PubMed Web of Science ®Google Scholar
• Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM. Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J. 2012;8(2):103–10. doi:10.1007/s11420-012-9725-y
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24. doi:10.1002/art.1780310302
   PubMed Web of Science ®Google Scholar
• Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc. 1949;140(8):659–62. doi:10.1001/jama.1949.02900430001001
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23(5):S100.
   PubMed Web of Science ®Google Scholar
• Marotte H, Pallot-Prades B, Grange L, Gaudin P, Alexandre C, Miossec P. A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther. 2007;9(3):R61. doi:10.1186/ar2219
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, Klaasen R, Dijkgraaf MG, Gerlag DM, van Eck-Smit BL, Tak PP. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis. 2009;68(3):373–6. doi:10.1136/ard.2008.091611
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int. 2008;28(3):245–51. doi:10.1007/s00296-007-0419-1
   PubMed Web of Science ®Google Scholar
• Bertoldi l, Filippou G, Scirè CA, Picemo V, di Sabatino V, Pierquidi S, et al. Disease activity and bone density of mcp joints in patients with rheumatoid and psoriatic arthritis: is there a correlation? –a study inpatients treated with methotrexate and an anti-TNF a agent. ISRN Rheumatol. 2013;2013:708323. doi:10.1155/2013/708323
   PubMedGoogle Scholar
• Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–87. doi:10.1007/s001980200108
   PubMed Web of Science ®Google Scholar
• Glüer CC, Marin F, Ringe JD, Hawkins F, Möricke R, Papaioannu N, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 10-month results of the EuroGIOPs trial. J Bone Miner Res. 2013;28(6):1355–68. doi:10.1002/jbmr.1870
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65. doi:10.1056/NEJMoa050336
   PubMed Web of Science ®Google Scholar
• Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216–26. doi:10.1056/NEJMoa035725
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207–15. doi:10.1056/NEJMoa031975
   PubMed Web of Science ®Google Scholar
• Manabe T, Mori S, Mashiba T, Kaji Y, Iwata K, Komatsubara S, et al. Human parathyroid hormone (1-34) accelerates natural fracture healing process in the femoral osteotomy model of cynomolgus monkeys. Bone. 2007;40(6):1475–82. doi:10.1016/j.bone.2007.01.015
   PubMed Web of Science ®Google Scholar
• Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone(1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14(6):960–8. doi:10.1359/jbmr.1999.14.6.960
   PubMed Web of Science ®Google Scholar
• Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, et al. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1–34). J Bone Joint Surg Am. 2005;87(4):731–41. doi:10.2106/JBJS.D.02115
   PubMed Web of Science ®Google Scholar
• Bultink IE, Vis M, van der Horst-Brunisma IE, Lems WF. Inflammatory rheumatic disorders and bone. Curr Rheumatol Rep. 2012;14(3):224–30. doi:10.1007/s11926-012-0252-8
   PubMed Web of Science ®Google Scholar